Get the Stockscreener App
33.42
3.16%
-1.09
After Hours:
33.42
Korro Bio Inc stock is traded at $33.42, with a volume of 69,930.
It is down -3.16% in the last 24 hours and down -29.97% over the past month.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
See More
Previous Close:
$34.51
Open:
$34.26
24h Volume:
69,930
Relative Volume:
0.88
Market Cap:
$310.77M
Revenue:
-
Net Income/Loss:
$-81.17M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-82.84M
1W Performance:
-3.61%
1M Performance:
-29.97%
6M Performance:
-62.87%
1Y Performance:
+0.00%
1-Day Range:
$32.60
$35.18
1-Week Range:
$32.60
$36.69
52-Week Range:
$30.00
$97.91
Korro Bio Inc Stock (KRRO) Company Profile
Name
Korro Bio Inc
Sector
Industry
Phone
617-468-1999
Address
ONE KENDALL SQUARE. BUILDING 600-700, CAMBRIDGE
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-24 | Reiterated | H.C. Wainwright | Buy |
| Feb-27-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-04-23 | Initiated | H.C. Wainwright | Buy |
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-10-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-13-23 | Downgrade | Cowen | Outperform → Market Perform |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jan-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-28-19 | Initiated | Cowen | Outperform |
| Oct-28-19 | Initiated | Goldman | Buy |
| Oct-28-19 | Initiated | JP Morgan | Overweight |
View All
Korro Bio Inc Stock (KRRO) Latest News
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for growth - Investing.com
Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society - The Manila Times
116,858 Shares in Korro Bio, Inc. (NASDAQ:KRRO) Bought by Driehaus Capital Management LLC - MarketBeat
NEA Management Company LLC Boosts Stock Position in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
19,148 Shares in Korro Bio, Inc. (NASDAQ:KRRO) Bought by Bank of New York Mellon Corp - MarketBeat
19,148 Shares in Korro Bio, Inc. (NASDAQ:KRRO) Purchased by Bank of New York Mellon Corp - Defense World
Tri Locum Partners LP Takes Position in Korro Bio, Inc. (NASDAQ:KRRO) - MarketBeat
Brown Brothers Harriman & Co. Acquires Shares of 813 Korro Bio, Inc. (NASDAQ:KRRO) - Defense World
Stock Surge: Corcept Therapeutics Inc (CORT) Closes at 40.92, Marking a -3.19 Increase/Decrease - The Dwinnex
Korro Bio, Inc. Forecasted to Post Q3 2024 Earnings of ($2.79) Per Share (NASDAQ:KRRO) - MarketBeat
Korro Bio (NASDAQ:KRRO) Given "Outperform" Rating at Royal Bank of Canada - MarketBeat
Korro Bio (NASDAQ:KRRO) Given “Outperform” Rating at Royal Bank of Canada - Defense World
Korvest Ltd Director Buys First Shares - TipRanks
Korro Bio - The Pharma Letter
ORGN stock touches 52-week high at $1.73 amid market optimism - Investing.com Australia
Research Analysts Offer Predictions for Oruka Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:ORKA) - Defense World
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks - MSN
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks - The Motley Fool
HC Wainwright Reiterates “Buy” Rating for Korro Bio (NASDAQ:KRRO) - Defense World
Corcept Therapeutics (NASDAQ:CORT) Price Target Raised to $67.00 - MarketBeat
A look at CORT’s current quarter earnings estimates - US Post News
Korro Bio (NASDAQ:KRRO) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Korro Bio shares hold Outperform rating on significant partnership By Investing.com - Investing.com Canada
Korro Bio and Novo Nordisk Collaborate on Cardiometabolic Treatments - Pharmaceutical Technology Magazine
Crude Oil Gains Over 1%; US Business Inventories Increase In July - Benzinga
Corcept Therapeutics (NASDAQ:CORT) Hits New 12-Month High at $39.97 - MarketBeat
Korro Bio shares hold Outperform rating on significant partnership - Investing.com
Korro Bio and Novo Nordisk partner to advance genetic medicines for cardiometabolic disease - BioWorld Online
H.C. Wainwright maintains Korro Bio shares at Buy rating with no change in target price - Investing.com
Korro Bio inks cardiometabolics deal with Novo Nordisk - The Pharma Letter
Headlands Technologies LLC Acquires New Holdings in Organon & Co. (NYSE:OGN) - Defense World
Korro Bio partners with Novo Nordisk on RNA editing therapies By Investing.com - Investing.com Canada
Novo Nordisk, Korro Bio partner to develop new genetic medicines - World Pharmaceutical Frontiers
Novo Nordisk and Korro Bio Collaborate on Cardiometabolic Treatments - BioPharm International
Cambridge biotech’s deal with Novo Nordisk worth up to $530M - The Business Journals
Korro Bio partners with Novo Nordisk on RNA editing therapies By Investing.com - Investing.com Australia
Korro Bio partners with Novo Nordisk on RNA editing therapies - Investing.com
Novo Nordisk signs $530M biobucks deal to sing in Korro's opera - Fierce Biotech
Korro Bio partners with Novo Nordisk to develop two drug candidates - MedWatch
Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates - StockTitan
Korro Bio, Inc. (NASDAQ:KRRO) is Atlas Venture Life Science Advisors LLC's 6th Largest Position - MarketBeat
Korro to Participate in Upcoming Investor Conferences - StockTitan
Will Korro Bio (NASDAQ:KRRO) Spend Its Cash Wisely? - Yahoo Finance
Short Interest in Korro Bio, Inc. (NASDAQ:KRRO) Expands By 5.1% - MarketBeat
A Guide To The Risks Of Investing In Korro Bio Inc. (KRRO) - Knox Daily
Korro Bio appoints new director, Lucchino resigns - Investing.com
Korro Bio appoints new director, Lucchino resigns By Investing.com - Investing.com UK
Korro to Participate in Upcoming September Investor and Scientific Conferences - StockTitan
Korro Bio, Inc. Announces Resignation of Steve Colletti as Chief Scientific Officer, Effective August 2, 2024 - Marketscreener.com
KRRO Stock Earnings: Korro Bio Misses EPS for Q2 2024 - MSN
Korro Bio’s (KRRO) “Buy” Rating Reiterated at HC Wainwright - Defense World
Korro Bio Inc Stock (KRRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):